Drugs and FDA

Roche and Zealand report phase 2 petrelintide weight-loss results

In the phase 2 trial, the 5 mg dose reduced mean body weight by 9.8% at 28 weeks, compared with 1.7% with placebo.

Reported by 2 outlets Thursday, October 1, 2026

Pink tablets in a blister pack
Photo: CC0

Roche and Zealand Pharma reported expanded phase 2 results for petrelintide, an investigational amylin drug for weight loss. The ZUPREME 1 trial included 485 patients with overweight or obesity who did not have type 2 diabetes, according to Healio. Results were presented at the European Association for the Study of Diabetes annual meeting and published in The Lancet Diabetes & Endocrinology.

At 28 weeks, mean weight loss was 9.8% with the 5 mg dose, compared with 7.9% with the 1 mg and 2.5 mg doses, 9.3% with 7 mg, 9.4% with 9 mg and 1.7% with placebo, Healio reported. At 42 weeks, weight loss reached 10.7% with 5 mg and 1.7% with placebo in the efficacy analysis. Fierce Biotech reported a different analysis found weight reductions of up to 10.2% at 42 weeks, compared with 1.4% for placebo.

Nausea occurred in 20% of petrelintide participants and 6% of placebo participants, according to Healio. Fierce Biotech reported that Roche was scheduled to start three phase 3 studies of the drug, targeting people with obesity or overweight, including groups with type 2 diabetes or cardiovascular disease.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.